Abstract:CCR5, a chemokine receptor central for orchestrating lymphocyte/cell migration to the sites of inflammation and to the immunosurveillance, is involved in the pathogenesis of a wide spectrum of health conditions, including inflammatory diseases, viral infections, cancers and autoimmune diseases. CCR5 is also the primary coreceptor for the human immunodeficiency viruses (HIVs), supporting its entry into CD4 + T lymphocytes upon transmission and in the early stages of infection in humans. A natural loss-of-function mutation CCR5-Δ32, preventing the mutated protein expression on the cell surface, renders homozygous carriers of the null allele resistant to HIV-1 infection. This phenomenon was leveraged in the development of therapies and cure strategies for AIDS. Meanwhile, over 40 African nonhuman primate species are long-term hosts of simian immunodeficiency virus (SIV), an ancestral family of viruses that give rise to the pandemic CCR5 (R5)-tropic HIV-1. Many natural hosts typically do not progress to immunodeficiency upon the SIV infection. They have developed various strategies to minimize the SIV-related pathogenesis and disease progression, including an array of mechanisms employing modulation of the CCR5 receptor activity: (i) deletion mutations abrogating the CCR5 surface expression and conferring resistance to infection in null homozygotes; (ii) downregulation of CCR5 expression on CD4 + T cells, particularly memory cells and cells at the mucosal sites, preventing SIV from infecting and killing cells important for the maintenance of immune homeostasis, (iii) delayed onset of CCR5 expression on the CD4 + T cells during ontogenetic development that protects the offspring from vertical transmission of the virus. These host adaptations, aimed at lowering the availability of target CCR5 + CD4 + T cells through CCR5 downregulation, were countered by SIV, which evolved to alter the entry coreceptor usage toward infecting different CD4 + T-cell subpopulations that support viral replication yet without disruption of host immune homeostasis. These natural strategies against SIV/HIV-1 infection, involving control of CCR5 function, inspired therapeutic approaches against HIV-1 disease, employing CCR5 coreceptor blocking as well as gene editing and silencing of CCR5. Given the pleiotropic role of CCR5 in health beyond immune disease, the precision as well as costs and benefits of such interventions needs to be carefully considered.

High Level Expression, Purification and Characterization of Recombinant CCR5 As a Vaccine Candidate Against HIV.

Construction, Purification, and Immunogenicity of Recombinant Cystein-Cystein Type Chemokine Receptor 5 Vaccine.

Establishment and characterization of CHO cell line stably expressing human CCR5 gene

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Chemokine Receptor Ccr5 Functionally Couples to Inhibitory G Proteins and Undergoes Desensitization

Construction and Characterization of Plasmid Expressing Human CCR5 Gene in Eukaryotes

Establishment of A New Cell Line for High-Throughput Evaluation of Chemokine Ccr5 Receptor Antagonists

Generation and Characterization of a Bivalent HIV-1 Subtype C Gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

Expression, Purification, and Renaturation of a Recombinant Peptide-Based HIV Vaccine in Escherichia Coli.

A Novel Recombinant Chemokine Protein TAT-SDF-1/54-KDEL for Blocking CXCR4: Bioinformatics Analysis and Prokaryotic Expression (CCR5P.263)

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody.

Advances of CCR5 antagonists: From small molecules to macromolecules

CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair

Targeting CCR5 for anti-HIV research

CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine

Construction and Purification of the Recombinant Adenoviral Vector Carrying Antisense RNA to Chemokine Receptor CCR5

A Novel Therapeutic Vaccination Delays Cart-Resistant Hiv-1 Reservoir Rebound in Hiv-1 Infected Humanized Mice

Recent advances in the development of small-molecule CCR5 inhibitors for HIV.

Preparation and Characterization of a New Monoclonal Antibody Against CXCR4 Using Lentivirus Vector.

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy